Lunch time seminar Thermo Fisher Scientific
Monday, April 11, 2016 from 1–2 pm in room D203 and D204.
|Customised solutions for microbial genomics and antimicrobial susceptibility tests|
|13:00||Welcome from Thermo Fisher Scientific|
|13:05||A case study of AST at Aarhus University Hospital, Denmark
Dorte Paulmann, Biomedical Scientist, Dept. of Clinical Microbiology, Aarhus University Hospital, Denmark
Abstract to follow
|13:30||Ion Torrent™ next-generation sequencing provides new insights on polymicrobial infections
Oyvind Kommedal MD, PhD, Consultant, Dept. of Microbiology, Haukeland University Hospital, Norway
We explored the potential of massive parallel sequencing (MPS) for improving the detection of polymicrobial infections, using bacterial brain abscesses as an example. Bacterial 16S rRNA genes were amplified directly from the specimens and sequenced using Ion Torrent™ technology, with an average of 500,000 reads per sample. The results were compared to those from culture- and Sanger sequencing-based methods. Compared to culture, MPS allowed for triple the number of bacterial identifications and it can accurately describe polymicrobial specimens when a sufficient number of reads is used to compensate for unequal species concentrations. This will contribute to our understanding of how different types of polymicrobial infections develop.
|13:45||Molecular detection of antimicrobial susceptibility: Changing paradigm of laboratory testing for multidrug resistant organisms
Leslie Malone, PhD, Associate Director R&D, Diatherix Laboratories, AL, USA
Rapid molecular testing can offer a change in paradigm for susceptibility testing and can potentially have a significant impact on patient care. In this study, a molecular panel of TaqMan™ assays was designed to detect twenty-six multidrug-resistance genes encoding the most clinically prevalent mechanisms of resistance to four major classes of antibiotics: aminoglycosides, β-lactams, fluoroquinolones, and macrolides. The validation of target specificity of these TaqMan assays using samples with known, sequence-validated resistance profiles resulted in 100% concordance with the previous results. We conclude that the direct testing on multidrug resistant organisms with a high-throughput TaqMan assay panel may provide a powerful tool that can be utilized in clinical settings to lower healthcare costs, reduce unnecessary antibiotic use, and improve patient care.
Register now to book your seat.